Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells

Overview of attention for article published in Frontiers in oncology, May 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 2 X users, with an upper bound of 23,814 followers.

Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells https://t.co/zIfEPZNvO7 https://t.co/hTq2coxsIy

07 Jun 2023

Reply Repost Favourite

Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells https://t.co/WLB1iV6njo https://t.co/PwD2bwIJFn

07 Jun 2023

Reply Repost Favourite

New research: Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells: Emerging evidence suggests that chemotherapeutic agents and targeted… #oncology http

31 May 2023

Reply Repost Favourite

📄 How effective are non-oncology drugs as cancer therapies? 👨‍⚕️👩‍⚕️ Yulu Wang et al Available here #OpenAccess 👉 https://t.co/jm3FA0CESx #openaccess

31 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.